Tirzepatide Once Weekly for the Treatment of Obesity
In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by ...
Publications
2 shownTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 we...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,988
- Institution
- Eli Lilly (United States)
External Links
Identifiers
- ORCID
- 0000-0003-2029-5187
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.